Loading...

Robert Grant, MD, MPH

TitleProfessor
SchoolUCSF School of Medicine
DepartmentMedicine
Address1650 3rd St
San Francisco CA 94158
Phone415-734-4810
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco Residency School of Medicine
    University of California, San FranciscoM.D.1988 Medicine
    University of California, San FranciscoM.S.1986 Medicine

    Collapse Overview 
    Collapse Overview
    Dr. Grant received in his M.D. degree from the University of California, San Francisco in 1988. Dr. Grant then completed a research fellowship in Molecular Medicine at University of California, San Francisco. After internal medicine, pulmonary subspecialty, and research training at University of California, San Francisco and the Gladstone Institute of Virology and Immunology, he joined the faculty of University of California, San Francisco in 1996. His major academic activities include directing the Gladstone-UCSF Laboratory of Clinical Virology, serving as Associate Director of the UCSF Center for AIDS Research, directing a research laboratory, and clinical practice in the Division of Pulmonary and Critical Care Medicine at San Francisco General Hospital.

    Research Interests

    I have 16 years of experience with HIV-1 related treatment and research, including 13 years of clinical experience caring for persons with AIDS, 2 years experience as a data analyst with the San Francisco Men’s Health Study, 2 years experience as an epidemiologist in Uganda, and 6 years experience in basic science laboratories at the Gladstone Institute of Virology and Immunology. My overall goal is to understand the biological basis for viral epidemic patterns, including host and viral evolution that underlies transmission between individual hosts and between host species.

    In August of 1997, I became the Director of the Gladstone/UCSF Laboratory of Clinical Virology located at San Francisco General Hospital. The laboratory aims to bridge gaps between basic virology and problems of human health, especially AIDS. The laboratory is investigating (1) the prevalence of viral drug resistance in treated subjects and their sexual partners, (2) the transmissibility of drug resistant variants, (3) the viral fitness and cytopathicity of drug resistant variants, and (4) the role of host-directed therapy for targeting the reservoir of latently infected cells. The epidemic potential of drug resistant HIV-1 has been considered in mathematical models developed based on clinical and public health data from San Francisco. In addition, the laboratory supports a wide number and range of clinical and epidemiologic studies with "state-of-the-art" standardized virology assays.

    The clinical and immunologic consequences of virologic failure of antiretroviral therapy and antiretroviral resistance have become the focus of my active research interest. We have described that the majority of patients who virologically fail antiretroviral therapy have sustained increases in circulating CD4+ T lymphocyte counts. Although partial drug susceptibility maintains viremia below pre-treatment levels accounts in many subjects with drug-selected HIV-1, this does not account for all of the immunologic benefit that persists during therapy. Experiments in the laboratory now focus on the specific virulence and replication fitness of drug resistant HIV-1.


    Collapse Research 
    Collapse Research Activities and Funding
    Chemoprophylaxis and HIV Host Interactions
    NIH/NIAID R01AI118575May 1, 2015 - Apr 30, 2020
    Role: Principal Investigator
    The Biology of HIV Transmission
    NIH/NIAID P01AI071713Sep 1, 2007 - Aug 31, 2013
    Role: Co-Investigator
    Chemoprophylaxis for HIV Prevention in Men
    NIH/NIAID U01AI064002Dec 1, 2004 - Jan 31, 2013
    Role: Principal Investigator
    Chemoprophylaxis and HIV-Host Interactions
    NIH/NIAID R01AI062333Sep 1, 2004 - Mar 31, 2013
    Role: Principal Investigator
    Mechanisms Blocking HIV-1 Superinfection
    NIH/NIAID R01AI056988Dec 1, 2003 - May 30, 2008
    Role: Principal Investigator
    GENDER EFFECTS ON HIV BIOLOGY
    NIH/NICHD P01HD040543Apr 23, 2001 - Mar 31, 2008
    Role: Co-Investigator
    Support of Yerkes National Primate Research Center
    NIH P51RR000165Jun 1, 1976 - Apr 30, 2016
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000083Oct 1, 1974 - Nov 30, 2007
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant R. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. J Acquir Immune Defic Syndr. 2017 Oct 01; 76(2):177-182. PMID: 28639995.
      View in: PubMed
    2. Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, Mohri H. Newly Acquired Infection with Multi-Drug Resistant HIV-1 in a Patient Adherent to Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr. 2017 Aug 26. PMID: 28857937.
      View in: PubMed
    3. Lal L, Audsley J, Murphy DA, Fairley CK, Stoove M, Roth N, Moore R, Tee BK, Puratmaja N, Anderson PL, Leslie D, Grant R, De Wit J, Wright E. Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. AIDS. 2017 Jul 31; 31(12):1709-1714. PMID: 28700394.
      View in: PubMed
    4. Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. J Acquir Immune Defic Syndr. 2017 Jul 01; 75(3):271-279. PMID: 28328548.
      View in: PubMed
    5. Markowitz M, Frank I, Grant R, Mayer KH, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Van Tieu H, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart AR, Smith KY, Spreen WR. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017 Aug; 4(8):e331-e340. PMID: 28546090.
      View in: PubMed
    6. Seidman DL, Weber S, Grant R. Is pericoital or peri-insemination preexposure prophylaxis effective human immunodeficiency prevention for vaginal exposures? Am J Obstet Gynecol. 2017 Aug; 217(2):230-231. PMID: 28479285.
      View in: PubMed
    7. Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, Dye BJ, Elharrar V, Grant R. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. AIDS Behav. 2017 May; 21(5):1361-1375. PMID: 27317411.
      View in: PubMed
    8. Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant R, Rodolph M, Hodges-Mameletzis I, Kennedy CE. Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature. AIDS Behav. 2017 May; 21(5):1325-1335. PMID: 27900502.
      View in: PubMed
    9. Truong HM, Mehrotra M, Montoya O, Lama JR, Guanira JV, Casapía M, Veloso VG, Buchbinder SP, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant R. International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. Sex Transm Dis. 2017 May; 44(5):306-309. PMID: 28407648.
      View in: PubMed
    10. Koester K, Amico RK, Gilmore H, Liu A, McMahan V, Mayer K, Hosek S, Grant R. Risk, safety and sex among male PrEP users: time for a new understanding. Cult Health Sex. 2017 Apr 18; 1-13. PMID: 28415911.
      View in: PubMed
    11. Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant R, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Res Hum Retroviruses. 2017 Mar 02. PMID: 28253024.
      View in: PubMed
    12. Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016; 19(7(Suppl 6)):21105. PMID: 27760683.
      View in: PubMed
    13. Glidden DV, Anderson PL, Grant R. Pharmacology supports on-demand PrEP. Lancet HIV. 2016 Sep; 3(9):e405-e406. PMID: 27562738.
      View in: PubMed
    14. Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant R, et al. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV. 2016 Nov; 3(11):e521-e528. PMID: 27658870.
      View in: PubMed
    15. Grant R, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB. Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr. 2016 Aug 15; 72 Suppl 3:S226-9. PMID: 27429187; PMCID: PMC4969062.
    16. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant R. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016 Jul 31; 30(12):1973-83. PMID: 27149090; PMCID: PMC4949005.
    17. Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, Mayer KH, Veloso VG, Bekker LG, Avelino-Silva VI, Schechter M, Grant R. The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. AIDS Behav. 2016 Jul; 20(7):1527-34. PMID: 27125241; PMCID: PMC4912836 [Available on 07/01/17].
    18. Defechereux PA, Mehrotra M, Liu AY, McMahan VM, Glidden DV, Mayer KH, Vargas L, Amico KR, Chodacki P, Fernandez T, Avelino-Silva VI, Burns D, Grant R. Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). AIDS Behav. 2016 Jul; 20(7):1478-88. PMID: 26078115; PMCID: PMC4903104.
    19. Truong HH, Chen YH, Grasso M, Robertson T, Tao L, Fatch R, Curotto A, McFarland W, Grant R, Reznick O, Raymond HF, Steward WT. HIV Serodisclosure and Sexual Behavior During International Travel. Sex Transm Dis. 2016 07; 43(7):459-64. PMID: 27322049; PMCID: PMC4920132 [Available on 07/01/17].
    20. Kuebler PJ, Shaw BI, Leadabrand KS, Mehrotra ML, Grant R, Kallás EG, Nixon DF. Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial. J Acquir Immune Defic Syndr. 2016 Jun 01; 72(2):184-8. PMID: 26674373.
      View in: PubMed
    21. Sevelius J, Deutsch MB, Glidden DV, Grant R. PrEP adherence among trans women in Brazil-access needed for this key population - Authors' reply. Lancet HIV. 2016 May; 3(5):e200-1. PMID: 27126486.
      View in: PubMed
    22. Zamperlini-Netto G, Zanette A, Wehbi E, Williams S, Grant R, Brandao LR. PO-60 - Renal tumors with extensive vascular disease: management challenges in a pediatric series from the Hospital for Sick Children. Thromb Res. 2016 Apr; 140 Suppl 1:S198-9. PMID: 27161746.
      View in: PubMed
    23. Grant R, Glidden DV. HIV moments and pre-exposure prophylaxis. Lancet. 2016 Apr 09; 387(10027):1507-8. PMID: 27115970.
      View in: PubMed
    24. Yacoub R, Nadkarni GN, Weikum D, Konstantinidis I, Boueilh A, Grant R, Mugwanya KK, Baeten JM, Wyatt CM. Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials. J Acquir Immune Defic Syndr. 2016 Apr 01; 71(4):e115-8. PMID: 26627105; PMCID: PMC4767606 [Available on 04/01/17].
    25. Solomon MM, Schechter M, Liu AY, Mcmahan VM, Guanira JV, Hance RJ, Chariyalertsak S, Mayer KH, Grant R. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. J Acquir Immune Defic Syndr. 2016 Mar 01; 71(3):281-6. PMID: 26413853; PMCID: PMC4752387.
    26. Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, Burns D, Schechter M, Grinsztejn B, Guanira J, Grant R. Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis. 2016 May 01; 62(9):1172-7. PMID: 26797207; PMCID: PMC4826449 [Available on 05/01/17].
    27. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med. 2016 Jan; 176(1):75-84. PMID: 26571482.
      View in: PubMed
    28. Grant R, Koester KA. What people want from sex and preexposure prophylaxis. Curr Opin HIV AIDS. 2016 Jan; 11(1):3-9. PMID: 26569183.
      View in: PubMed
    29. Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant R. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015 Dec; 2(12):e512-9. PMID: 26614965.
      View in: PubMed
    30. Koester KA, Grant R. Editorial Commentary: Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis. Clin Infect Dis. 2015 Nov 15; 61(10):1604-5. PMID: 26334051; PMCID: PMC4614416.
    31. Grant R, Smith DK. Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment. Open Forum Infect Dis. 2015 Dec; 2(4):ofv126. PMID: 26512356; PMCID: PMC4621406.
    32. Kuebler PJ, Mehrotra ML, Shaw BI, Leadabrand KS, Milush JM, York VA, Defechereux P, Grant R, Kallás EG, Nixon DF. Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation. J Infect Dis. 2016 Feb 15; 213(4):569-73. PMID: 26310308; PMCID: PMC4721903 [Available on 02/15/17].
    33. Truong HH, Pipkin S, O'Keefe KJ, Louie B, Liegler T, McFarland W, Grant R, Bernstein K, Scheer S. Brief Report: Recent Infection, Sexually Transmitted Infections, and Transmission Clusters Frequently Observed Among Persons Newly Diagnosed With HIV in San Francisco. J Acquir Immune Defic Syndr. 2015 Aug 15; 69(5):606-9. PMID: 25967271; PMCID: PMC4501865.
    34. Kuebler PJ, Mehrotra ML, McConnell JJ, Holditch SJ, Shaw BI, Tarosso LF, Leadabrand KS, Milush JM, York VA, Raposo RA, Cheng RG, Eriksson EM, McMahan V, Glidden DV, Shiboski S, Grant R, Nixon DF, Kallás EG. Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8379-84. PMID: 26100867; PMCID: PMC4500209.
    35. Weber S, Grant R. Ending sexual HIV transmission: lessons learned from perinatal HIV. J Assoc Nurses AIDS Care. 2015 Sep-Oct; 26(5):520-5. PMID: 26096627.
      View in: PubMed
    36. Seidman D, Weber S, Aaron E, Cohan D, Grant R. The FACTS about women and pre-exposure prophylaxis. Lancet HIV. 2015 Jun; 2(6):e228. PMID: 26423194.
      View in: PubMed
    37. Koester KA, Liu A, Eden C, Amico KR, McMahan V, Goicochea P, Hosek S, Mayer KH, Grant R. Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study. AIDS Care. 2015; 27(10):1199-204. PMID: 26001026.
      View in: PubMed
    38. Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant R. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis. 2015 Aug 15; 61(4):572-80. PMID: 25908682; PMCID: PMC4565984.
    39. Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, Guanira JV, Grinsztejn B, Chariyalertsak S, Bekker LG, Grant R. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. J Infect Dis. 2015 Nov 01; 212(9):1402-6. PMID: 25895984; PMCID: PMC4601920 [Available on 11/01/16].
    40. Grant R, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Damme LV. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015 Jan 28; 29(3):331-7. PMID: 25503265.
      View in: PubMed
    41. Grant R, Liegler T. Weighing the risk of drug resistance with the benefits of HIV preexposure prophylaxis. J Infect Dis. 2015 Apr 15; 211(8):1202-4. PMID: 25587019; PMCID: PMC4371769.
    42. Gesner M, Maiti M, Grant R, Cavrois M. Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24Gag. Bio Protoc. 2014 Dec 20; 4(24). PMID: 27525295.
      View in: PubMed
    43. Solomon MM, Nureña CR, Tanur JM, Montoya O, Grant R, Jeff McConnell J. Transactional sex and prevalence of STIs: a cross-sectional study of MSM and transwomen screened for an HIV prevention trial. Int J STD AIDS. 2015 Oct; 26(12):879-86. PMID: 25520017; PMCID: PMC4470879.
    44. Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant R. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014 Dec 15; 67(5):528-37. PMID: 25230290; PMCID: PMC4229454.
    45. Guanira JV, Leigler T, Kallas E, Schechter M, Sharma U, Glidden D, Grant R. Streamlining HIV testing for HIV preexposure prophylaxis. J Clin Microbiol. 2015 Jan; 53(1):179-83. PMID: 25378570; PMCID: PMC4290918.
    46. Truong HH, Fatch R, Grasso M, Robertson T, Tao L, Chen YH, Curotto A, McFarland W, Grant R, Reznick O, Raymond HF, Steward WT. Gay and bisexual men engage in fewer risky sexual behaviors while traveling internationally: a cross-sectional study in San Francisco. Sex Transm Infect. 2015 May; 91(3):220-5. PMID: 25355773.
      View in: PubMed
    47. Solomon MM, Mayer KH, Glidden DV, Guanira JV, Grant R. Reply to Boyd et al. Clin Infect Dis. 2015 Jan 15; 60(2):327. PMID: 25323702; PMCID: PMC4275063.
    48. Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, Anderson PL, Glidden D, Guanira J, Grant R. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr. 2014 Aug 15; 66(5):530-7. PMID: 24853306; PMCID: PMC4110718.
    49. Miller V, Grant R. Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition. Clin Pharmacol Ther. 2014 Aug; 96(2):153-5. PMID: 25056397.
      View in: PubMed
    50. Grant R, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, Hosek S, Mosquera C, Casapia M, Montoya O, Buchbinder S, Veloso VG, Mayer K, Chariyalertsak S, Bekker LG, Kallas EG, Schechter M, Guanira J, Bushman L, Burns DN, Rooney JF, Glidden DV. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014 Sep; 14(9):820-9. PMID: 25065857.
      View in: PubMed
    51. Marrazzo JM, del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH, Montaner JS, Wheeler DP, Grant R, Grinsztejn B, Kumarasamy N, Shoptaw S, Walensky RP, Dabis F, Sugarman J, Benson CA. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014 Jul 23-30; 312(4):390-409. PMID: 25038358.
      View in: PubMed
    52. Solomon MM, Mayer KH, Glidden DV, Liu AY, McMahan VM, Guanira JV, Chariyalertsak S, Fernandez T, Grant R. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial. Clin Infect Dis. 2014 Oct; 59(7):1020-6. PMID: 24928295; PMCID: PMC4166980.
    53. Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant R. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014 Oct 15; 210(8):1217-27. PMID: 24740633; PMCID: PMC4176446.
    54. Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, Guanira JV, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Burns DN, Grant R. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014 Mar 27; 28(6):851-9. PMID: 24499951; PMCID: PMC3966916.
    55. Marcus JL, Glidden DV, McMahan V, Lama JR, Mayer KH, Liu AY, Montoya-Herrera O, Casapia M, Hoagland B, Grant R. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. PLoS One. 2014; 9(3):e91513. PMID: 24637511; PMCID: PMC3956614.
    56. Buchbinder SP, Glidden DV, Liu AY, McMahan V, Guanira JV, Mayer KH, Goicochea P, Grant R. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis. 2014 Jun; 14(6):468-75. PMID: 24613084; PMCID: PMC4133171.
    57. Marcus JL, Buisker T, Horvath T, Amico KR, Fuchs JD, Buchbinder SP, Grant R, Liu AY. Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions. HIV Med. 2014 Aug; 15(7):385-95. PMID: 24580813; PMCID: PMC4107052.
    58. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014; 9(1):e83736. PMID: 24421901; PMCID: PMC3885443.
    59. Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant R. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One. 2013; 8(12):e81997. PMID: 24367497; PMCID: PMC3867330.
    60. Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, Collins BM, Pathak SR, O'hara B, Ackers ML, Rose CE, Grant R, Paxton LA, Buchbinder SP. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013 Sep 01; 64(1):79-86. PMID: 23466649.
      View in: PubMed
    61. Vallabhaneni S, McConnell JJ, Loeb L, Hartogensis W, Hecht FM, Grant R, Pilcher CD. Changes in seroadaptive practices from before to after diagnosis of recent HIV infection among men who have sex with men. PLoS One. 2013; 8(2):e55397. PMID: 23405145; PMCID: PMC3566177.
    62. Gomez GB, Borquez A, Caceres CF, Segura ER, Grant R, Garnett GP, Hallett TB. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med. 2012; 9(10):e1001323. PMID: 23055836; PMCID: PMC3467261.
    63. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant R. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012 Sep 12; 4(151):151ra125. PMID: 22972843; PMCID: PMC3721979.
    64. R Amico K, McMahan V, Goicochea P, Vargas L, Marcus JL, Grant R, Liu A. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012 Jul; 16(5):1243-59. PMID: 22460228.
      View in: PubMed
    65. Truong HM, Kellogg TA, McFarland W, Louie B, Klausner JD, Philip SS, Grant R. Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS One. 2011; 6(10):e25281. PMID: 22046237; PMCID: PMC3189011.
    66. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, Janini LM, Liegler T, Pilcher CD, Grant R, Cortes R, Deeks SG, Hecht FM. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis. 2011 Apr 15; 203(8):1174-81. PMID: 21451005; PMCID: PMC3107558.
    67. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher CD, Grant R, Deeks SG, Hecht FM. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One. 2010 Dec 10; 5(12):e15510. PMID: 21170322; PMCID: PMC3000814.
    68. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant R. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011 Feb; 66(2):240-50. PMID: 21118913; PMCID: PMC3019086.
    69. Grant R, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30; 363(27):2587-99. PMID: 21091279; PMCID: PMC3079639.
    70. Grant R. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S96-101. PMID: 20397962; PMCID: PMC3663282.
    71. Hecht FM, Hartogensis W, Bragg L, Bacchetti P, Atchison R, Grant R, Barbour J, Deeks SG. HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS. 2010 Apr 24; 24(7):941-5. PMID: 20168202; PMCID: PMC2887742.
    72. McConnell JJ, Bragg L, Shiboski S, Grant R. Sexual seroadaptation: lessons for prevention and sex research from a cohort of HIV-positive men who have sex with men. PLoS One. 2010 Jan 21; 5(1):e8831. PMID: 20098616; PMCID: PMC2809110.
    73. Cardenas VA, Meyerhoff DJ, Studholme C, Kornak J, Rothlind J, Lampiris H, Neuhaus J, Grant R, Chao LL, Truran D, Weiner MW. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol. 2009 Jul; 15(4):324-33. PMID: 19499454; PMCID: PMC2889153.
    74. Truong HM, Kellogg T, Schwarcz S, Delgado V, Grant R, Louie B, Ngo H, McFarland W. Frequent international travel by men who have sex with men recently diagnosed with HIV-1: potential for transmission of primary HIV-1 drug resistance. J Travel Med. 2008 Nov-Dec; 15(6):454-6. PMID: 19090802.
      View in: PubMed
    75. Willberg CB, McConnell JJ, Eriksson EM, Bragg LA, York VA, Liegler TJ, Hecht FM, Grant R, Nixon DF. Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus. PLoS Pathog. 2008 Oct; 4(10):e1000185. PMID: 18949024; PMCID: PMC2562513.
    76. Erickson AL, Willberg CB, McMahan V, Liu A, Buchbinder SP, Grohskopf LA, Grant R, Nixon DF. Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level. Clin Vaccine Immunol. 2008 Nov; 15(11):1745-8. PMID: 18815234; PMCID: PMC2583520.
    77. Grant R, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA. Whither or wither microbicides? Science. 2008 Jul 25; 321(5888):532-4. PMID: 18653884; PMCID: PMC2835691.
    78. Bourara K, Liegler TJ, Grant R. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog. 2007 Oct 26; 3(10):1477-85. PMID: 17967058; PMCID: PMC2042017.
    79. Grant R. Research in situ. Nat Methods. 2007 Nov; 4(11):887-90. PMID: 17952085.
      View in: PubMed
    80. Abrams DI, Shade SB, Couey P, McCune JM, Lo J, Bacchetti P, Chang B, Epling L, Liegler T, Grant R. Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study. AIDS Res Hum Retroviruses. 2007 Jan; 23(1):77-85. PMID: 17263636.
      View in: PubMed
    81. Truong HM, Truong HH, Kellogg T, Klausner JD, Katz MH, Dilley J, Knapper K, Chen S, Prabhu R, Grant R, Louie B, McFarland W. Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? Sex Transm Infect. 2006 Dec; 82(6):461-6. PMID: 17151031; PMCID: PMC2563862.
    82. Stopak KS, Chiu YL, Kropp J, Grant R, Greene WC. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem. 2007 Feb 09; 282(6):3539-46. PMID: 17110377.
      View in: PubMed
    83. Truong HM, Grant R, McFarland W, Kellogg T, Kent C, Louie B, Wong E, Klausner JD. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS. 2006 Nov 14; 20(17):2193-7. PMID: 17086059.
      View in: PubMed
    84. Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kelleher AD, Routy JP, Campbell TB, Rosenberg ES, Segal MR, Weidler J, Grant R. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS. 2006 Oct 24; 20(16):2123-5. PMID: 17053362.
      View in: PubMed
    85. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant R, de Noronha CM, Weyrich AS, Greene WC, Planelles V. Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol. 2006 Nov; 80(21):10407-18. PMID: 16956949; PMCID: PMC1641771.
    86. Grant R, Wainberg MA. Chemoprophylaxis of HIV infection: moving forward with caution. J Infect Dis. 2006 Oct 01; 194(7):874-6. PMID: 16960773.
      View in: PubMed
    87. Levy V, Grant R. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis. 2006 Oct 01; 43(7):904-10. PMID: 16941375.
      View in: PubMed
    88. Liu AY, Grant R, Buchbinder SP. Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA. 2006 Aug 16; 296(7):863-5. PMID: 16905792.
      View in: PubMed
    89. Lama JR, Sanchez J, Suarez L, Caballero P, Laguna A, Sanchez JL, Whittington WL, Celum C, Grant R. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr. 2006 Aug 01; 42(4):501-5. PMID: 16773026.
      View in: PubMed
    90. Sánchez MS, Grant R, Porco TC, Getz WM. HIV drug-resistant strains as epidemiologic sentinels. Emerg Infect Dis. 2006 Feb; 12(2):191-7. PMID: 16494741; PMCID: PMC3373094.
    91. Gange SJ, Schneider MF, Grant R, Liegler T, French A, Young M, Anastos K, Wilson TE, Ponath C, Greenblatt R. Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure. J Acquir Immune Defic Syndr. 2006 Jan 01; 41(1):68-74. PMID: 16340476.
      View in: PubMed
    92. Chin-Hong PV, Deeks SG, Liegler T, Hagos E, Krone MR, Grant R, Martin JN. High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection. J Acquir Immune Defic Syndr. 2005 Dec 01; 40(4):463-71. PMID: 16280703.
      View in: PubMed
    93. Roland ME, Neilands TB, Krone MR, Katz MH, Franses K, Grant R, Busch MP, Hecht FM, Shacklett BL, Kahn JO, Bamberger JD, Coates TJ, Chesney MA, Martin JN. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis. 2005 Nov 15; 41(10):1507-13. PMID: 16231265.
      View in: PubMed
    94. Grant R, Buchbinder S, Cates W, Clarke E, Coates T, Cohen MS, Delaney M, Flores G, Goicochea P, Gonsalves G, Harrington M, Lama JR, MacQueen KM, Moore JP, Peterson L, Sanchez J, Thompson M, Wainberg MA. AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science. 2005 Sep 30; 309(5744):2170-1. PMID: 16195446.
      View in: PubMed
    95. Hecht FM, Grant R. Resistance testing in drug-naive HIV-infected patients: is it time? Clin Infect Dis. 2005 Nov 01; 41(9):1324-5. PMID: 16206109.
      View in: PubMed
    96. Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant R, Martin JN. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005 Nov 01; 192(9):1537-44. PMID: 16206068.
      View in: PubMed
    97. Neuenburg JK, Furlan S, Bacchetti P, Price RW, Grant R. Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. AIDS. 2005 Sep 02; 19(13):1351-9. PMID: 16103765.
      View in: PubMed
    98. Klausner JD, Grant R, Kent CK. Detection of acute HIV infections. N Engl J Med. 2005 Aug 11; 353(6):631-3; author reply 631-3. PMID: 16093476.
      View in: PubMed
    99. Neuenburg JK, Cho TA, Nilsson A, Bredt BM, Hebert SJ, Grant R, Price RW. T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection. J Acquir Immune Defic Syndr. 2005 May 01; 39(1):16-22. PMID: 15851909.
      View in: PubMed
    100. Barbour JD, Grant R. The role of viral fitness in HIV pathogenesis. Curr HIV/AIDS Rep. 2005 Feb; 2(1):29-34. PMID: 16091246.
      View in: PubMed
    101. Papasavvas E, Kostman JR, Mounzer K, Grant R, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med. 2004 Dec; 1(3):e64. PMID: 15630469; PMCID: PMC539050.
    102. Sánchez MS, Grant R, Porco TC, Gross KL, Getz WM. A decrease in drug resistance levels of the HIV epidemic can be bad news. Bull Math Biol. 2005 Jul; 67(4):761-82. PMID: 15893552.
      View in: PubMed
    103. Neuenburg JK, Sinclair E, Nilsson A, Kreis C, Bacchetti P, Price RW, Grant R. HIV-producing T cells in cerebrospinal fluid. J Acquir Immune Defic Syndr. 2004 Oct 01; 37(2):1237-44. PMID: 15385730.
      View in: PubMed
    104. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, Segal MR, Petropoulos CJ, Grant R. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS. 2004 Aug 20; 18(12):1683-9. PMID: 15280779.
      View in: PubMed
    105. Gross KL, Porco TC, Grant R. HIV-1 superinfection and viral diversity. AIDS. 2004 Jul 23; 18(11):1513-20. PMID: 15238769.
      View in: PubMed
    106. Reyes-Sandoval A, Fitzgerald JC, Grant R, Roy S, Xiang ZQ, Li Y, Gao GP, Wilson JM, Ertl HC. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol. 2004 Jul; 78(14):7392-9. PMID: 15220412; PMCID: PMC434124.
    107. Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, Busch MP, Petropoulos CJ, Hellmann NS, Kahn JO, Grant R. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis. 2004 Jul 15; 190(2):251-6. PMID: 15216458.
      View in: PubMed
    108. Barbour JD, Grant R. The Clinical Implications of Reduced Viral Fitness. Curr Infect Dis Rep. 2004 Apr; 6(2):151-158. PMID: 15023278.
      View in: PubMed
    109. Segal MR, Barbour JD, Grant R. Relating HIV-1 sequence variation to replication capacity via trees and forests. Stat Appl Genet Mol Biol. 2004; 3:Article2; discussion article 7, article 9. PMID: 16646798.
      View in: PubMed
    110. Angel JB, Hu YW, Kravcik S, Tsui R, Lee KH, Barbour J, Balaskas E, Branson BM, Delwart EL, Grant R. Virological evaluation of the 'Ottawa case' indicates no evidence for HIV-1 superinfection. AIDS. 2004 Jan 23; 18(2):331-4. PMID: 15075555.
      View in: PubMed
    111. Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant R, Osmond DH. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004 Jan 02; 18(1):81-8. PMID: 15090833; PMCID: PMC2442908.
    112. Tsui R, Herring BL, Barbour JD, Grant R, Bacchetti P, Kral A, Edlin BR, Delwart EL. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol. 2004 Jan; 78(1):94-103. PMID: 14671091; PMCID: PMC303392.
    113. Papasavvas E, Grant R, Sun J, Mackiewicz A, Pistilli M, Gallo C, Kostman JR, Mounzer K, Shull J, Montaner LJ. Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS. 2003 Nov 07; 17(16):2337-43. PMID: 14571185.
      View in: PubMed
    114. Bangsberg DR, Charlebois ED, Grant R, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003 Sep 05; 17(13):1925-32. PMID: 12960825.
      View in: PubMed
    115. Murphy EL, Grant R, Kropp J, Oliveira A, Lee TH, Busch MP. Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients. J Acquir Immune Defic Syndr. 2003 Aug 15; 33(5):655-6. PMID: 12902815.
      View in: PubMed
    116. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant R, Martin JN, Nixon DF. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol. 2003 Jun; 77(12):6743-52. PMID: 12767994; PMCID: PMC156163.
    117. D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant R, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. Drug resistance mutations in HIV-1. Top HIV Med. 2003 May-Jun; 11(3):92-6. PMID: 12837968.
      View in: PubMed
    118. Grant R, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd Jr RM, Reid C, Morgan GF, Winslow DL. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol. 2003 Apr; 41(4):1586-93. PMID: 12682149; PMCID: PMC153856.
    119. Kuritzkes DR, Grant R, Feorino P, Griswold M, Hoover M, Young R, Day S, Lloyd Jr RM, Reid C, Morgan GF, Winslow DL. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol. 2003 Apr; 41(4):1594-9. PMID: 12682150; PMCID: PMC153857.
    120. Asmuth DM, Kalish LA, Laycock ME, Murphy EL, Mohr BA, Lee TH, Gallarda J, Giachetti C, Dollard SC, van der Horst CM, Grant R, Busch MP. Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. Transfusion. 2003 Apr; 43(4):451-8. PMID: 12662277.
      View in: PubMed
    121. Hayden MS, Palacios EH, Grant R. Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays. AIDS. 2003 Mar 07; 17(4):629-31. PMID: 12598787.
      View in: PubMed
    122. Deeks SG, Grant R, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS. 2003 Feb 14; 17(3):361-70. PMID: 12556690.
      View in: PubMed
    123. Schweighardt B, Ortiz GM, Grant R, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS. 2002 Nov 22; 16(17):2342-4. PMID: 12441810.
      View in: PubMed
    124. Barbour JD, Wrin T, Grant R, Martin JN, Segal MR, Petropoulos CJ, Deeks SG. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol. 2002 Nov; 76(21):11104-12. PMID: 12368352; PMCID: PMC136622.
    125. D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant R, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. Drug Resistance Mutations in HIV-1. Top HIV Med. 2002 Nov-Dec; 10(5):21-25. PMID: 12717052.
      View in: PubMed
    126. Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, Grant R, Schlote W. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002 Oct 01; 31(2):171-7. PMID: 12394795.
      View in: PubMed
    127. Sandberg JK, Fast NM, Palacios EH, Fennelly G, Dobroszycki J, Palumbo P, Wiznia A, Grant R, Bhardwaj N, Rosenberg MG, Nixon DF. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol. 2002 Aug; 76(15):7528-34. PMID: 12097565; PMCID: PMC136353.
    128. Grant R, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002 Jul 10; 288(2):181-8. PMID: 12095382.
      View in: PubMed
    129. Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant R, Halvorsen RA, Schambelan M, McCune JM. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS. 2002 May 24; 16(8):1103-11. PMID: 12004268.
      View in: PubMed
    130. Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant R, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA. Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med. 2002 Mar 18; 195(6):719-36. PMID: 11901198; PMCID: PMC2193739.
    131. Deeks SG, Barbour JD, Grant R, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002 Jan 25; 16(2):201-7. PMID: 11807304.
      View in: PubMed
    132. Deeks SG, Hoh R, Grant R, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis. 2002 Feb 01; 185(3):315-23. PMID: 11807713.
      View in: PubMed
    133. Roland ME, Martin JN, Grant R, Hellmann NS, Bamberger JD, Katz MH, Chesney M, Franses K, Coates TJ, Kahn JO. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. J Infect Dis. 2001 Dec 15; 184(12):1608-12. PMID: 11740738.
      View in: PubMed
    134. Price RW, Paxinos EE, Grant R, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG. Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS. 2001 Jul 06; 15(10):1251-9. PMID: 11426069.
      View in: PubMed
    135. Stoddart CA, Liegler TJ, Mammano F, Linquist-Stepps VD, Hayden MS, Deeks SG, Grant R, Clavel F, McCune JM. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med. 2001 Jun; 7(6):712-8. PMID: 11385509.
      View in: PubMed
    136. Penn ML, Myers M, Eckstein DA, Liegler TJ, Hayden M, Mammano F, Clavel F, Deeks SG, Grant R, Goldsmith MA. Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res Hum Retroviruses. 2001 Apr 10; 17(6):517-23. PMID: 11350665.
      View in: PubMed
    137. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant R. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001 Feb 15; 344(7):472-80. PMID: 11172188.
      View in: PubMed
    138. Napolitano LA, Grant R, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, Herndier BG, Andersson J, McCune JM. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001 Jan; 7(1):73-9. PMID: 11135619.
      View in: PubMed
    139. Parkin NT, Deeks SG, Wrin MT, Yap J, Grant R, Lee KH, Heeren D, Hellmanna NS, Petropoulos CJ. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS. 2000 Dec 22; 14(18):2877-87. PMID: 11153669.
      View in: PubMed
    140. Celum CL, Buchbinder SP, Donnell D, Douglas JM, Mayer K, Koblin B, Marmor M, Bozeman S, Grant R, Flores J, Sheppard HW. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis. 2001 Jan 01; 183(1):23-35. PMID: 11106536.
      View in: PubMed
    141. Schramm B, Penn ML, Palacios EH, Grant R, Kirchhoff F, Goldsmith MA. Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J Virol. 2000 Oct; 74(20):9594-600. PMID: 11000231; PMCID: PMC112391.
    142. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant R. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000 Mar; 181(3):946-53. PMID: 10720517.
      View in: PubMed
    143. Huang SS, Barbour JD, Deeks SG, Huang JS, Grant R, Ng VL, McCune JM. Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis. 2000 Mar; 30(3):504-10. PMID: 10722435.
      View in: PubMed
    144. Blower SM, Gershengorn HB, Grant R. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science. 2000 Jan 28; 287(5453):650-4. PMID: 10649998.
      View in: PubMed
    145. Greenblatt RM, Ameli N, Grant R, Bacchetti P, Taylor RN. Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis. 2000 Jan; 181(1):82-90. PMID: 10608754.
      View in: PubMed
    146. Locher CP, Grant R, Collisson EA, Reyes-Terán G, Elbeik T, Kahn JO, Levy JA. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Hum Retroviruses. 1999 Dec 10; 15(18):1685-9. PMID: 10606091.
      View in: PubMed
    147. Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant R, Heyes M, Aweeka F, Deeks S, Price RW. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999 Jun 18; 13(9):1051-61. PMID: 10397535.
      View in: PubMed
    148. Staprans SI, Dailey PJ, Rosenthal A, Horton C, Grant R, Lerche N, Feinberg MB. Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol. 1999 Jun; 73(6):4829-39. PMID: 10233944; PMCID: PMC112526.
    149. Deeks SG, Hellmann NS, Grant R, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M, Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis. 1999 Jun; 179(6):1375-81. PMID: 10228057.
      View in: PubMed
    150. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant R. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999 Apr 16; 13(6):F35-43. PMID: 10397555.
      View in: PubMed
    151. Deeks SG, Grant R. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antivir Ther. 1999; 4 Suppl 3:7-11. PMID: 16021865.
      View in: PubMed
    152. Kaur A, Grant R, Means RE, McClure H, Feinberg M, Johnson RP. Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol. 1998 Dec; 72(12):9597-611. PMID: 9811693; PMCID: PMC110469.
    153. Hecht FM, Grant R, Petropoulos CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998 Jul 30; 339(5):307-11. PMID: 9682043.
      View in: PubMed
    154. Deeks SG, Grant R, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS. 1998 Jul 09; 12(10):F97-102. PMID: 9677159.
      View in: PubMed
    155. Palacios E, Digilio L, McClure HM, Chen Z, Marx PA, Goldsmith MA, Grant R. Parallel evolution of CCR5-null phenotypes in humans and in a natural host of simian immunodeficiency virus. Curr Biol. 1998 Jul 30-Aug 13; 8(16):943-6. PMID: 9707408.
      View in: PubMed
    156. McCune JM, Loftus R, Schmidt DK, Carroll P, Webster D, Swor-Yim LB, Francis IR, Gross BH, Grant R. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest. 1998 Jun 01; 101(11):2301-8. PMID: 9616201; PMCID: PMC508819.
    157. Grant R, Carver AD, Sloan RL. Multiple sclerosis in Fife. Scott Med J. 1998 Apr; 43(2):44-7. PMID: 9717204.
      View in: PubMed
    158. Grant R, Abrams DI. Not all is dead in HIV-1 graveyard. Lancet. 1998 Jan 31; 351(9099):308-9. PMID: 9652607.
      View in: PubMed
    159. Grant R, Piwowar EM, Katongole-Mbidde E, Muzawalu W, Rugera S, Abima J, Stramer SL, Kataaha P, Jackson B. Comparison of saliva and serum for human immunodeficiency virus type 1 antibody testing in Uganda using a rapid recombinant assay. Clin Diagn Lab Immunol. 1996 Nov; 3(6):640-4. PMID: 8914752; PMCID: PMC170424.
    160. Chuck S, Grant R, Katongole-Mbidde E, Conant M, Ganem D. Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma. J Infect Dis. 1996 Jan; 173(1):248-51. PMID: 8537669.
      View in: PubMed
    161. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant R, Feinberg MB. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995 Dec 01; 182(6):1727-37. PMID: 7500017; PMCID: PMC2192265.
    162. Kamya MR, Nsubuga P, Grant R, Hellman N. The high prevalence of genital herpes among patients with genital ulcer disease in Uganda. Sex Transm Dis. 1995 Nov-Dec; 22(6):351-4. PMID: 8578407.
      View in: PubMed
    163. Tsai CC, Follis KE, Sabo A, Grant R, Bischofberger N. Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J Infect Dis. 1995 May; 171(5):1338-43. PMID: 7538551.
      View in: PubMed
    164. Piwowar EM, Tugume SB, Grant R, Lutalo T, Pattishall K, Katongole-Mbidde E. beta-2 Microglobulin values among human immunodeficiency virus (HIV)-negative, HIV-positive asymptomatic, and HIV-positive symptomatic Ugandans. Clin Diagn Lab Immunol. 1995 Mar; 2(2):236-7. PMID: 7697536; PMCID: PMC170135.
    165. Tugume SB, Piwowar EM, Lutalo T, Mugyenyi PN, Grant R, Mangeni FW, Pattishall K, Katongole-Mbidde E. Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol. 1995 Mar; 2(2):233-5. PMID: 7697535; PMCID: PMC170134.
    166. Tan M, Klein R, Grant R, Ganem D, Engel J. Cloning and characterization of the RNA polymerase alpha-subunit operon of Chlamydia trachomatis. J Bacteriol. 1993 Nov; 175(22):7150-9. PMID: 8226662; PMCID: PMC206856.
    167. Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, Grant R, Crumpacker CS. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989 Feb 02; 320(5):293-6. PMID: 2536136.
      View in: PubMed
    168. Grant R, Hadley DM, Lang D, Condon B, Johnston R, Bone I, Teasdale GM. MRI measurement of syrinx size before and after operation. J Neurol Neurosurg Psychiatry. 1987 Dec; 50(12):1685-7. PMID: 3437304; PMCID: PMC1032615.
    169. Grant R, Wiley JA, Winkelstein W. Infectivity of the human immunodeficiency virus: estimates from a prospective study of homosexual men. J Infect Dis. 1987 Jul; 156(1):189-93. PMID: 3474298.
      View in: PubMed
    170. Winkelstein W, Lyman DM, Padian N, Grant R, Samuel M, Wiley JA, Anderson RE, Lang W, Riggs J, Levy JA. Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA. 1987 Jan 16; 257(3):321-5. PMID: 3540327.
      View in: PubMed
    171. Lang W, Anderson RE, Perkins H, Grant R, Lyman D, Winkelstein W, Royce R, Levy JA. Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome. The San Francisco Men's Health Study. JAMA. 1987 Jan 16; 257(3):326-30. PMID: 3491910.
      View in: PubMed
    172. Sandilands GP, Gray K, Cooney A, Browning JD, Grant R, Anderson JR, Dagg JH, Lucie N. Lymphocytes with T and B cell properties in a lymphoproliferative disorder. Lancet. 1974 May 11; 1(7863):903-4. PMID: 4133422.
      View in: PubMed
    Robert's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP